ERBB2 and neoplasm: Women with HER2-enriched tumours had the worst survival for those diagnosed between the ages of 50 to 69, whereas women with TNBC tumours had the worst survival for those diagnosed between the ages of 70 and 84 (Fig. 2, Table S1).